Targovax – Therapeutic cancer vaccines

Targovax is an innovation driven specialist in immuno-oncology.

People with identical cancer diagnoses do not have identical diseases. Their cells vary in the way they look, function and are seen by the immune system – the body’s own defence against cancer. At Targovax, we are developing cancer specific therapies that activate each patient’s own immune system to fight against their disease.

Read more

Even in late stage cancer patients with low immunogenic tumor types, our virus-based immunotherapy can reinstate the immune system’s ability to recognise and attack cancer cells. In addition, studies with our peptide-based Immunotherapy have shown immune responses in difficult to treat RAS cancer patients.

Read more

Hear from Magnus Jaderberg, CMO of Targovax on PharmaTV why its immuno-oncology pipeline offers something both different and complementary to the most exciting recent advances in this field.

Read more
  • Magnus Jaderberg, CMO of Targovax, has presented at a symposium by The Royal Swedish Academy of Engineering Sciences

    May 20, 2016

    Magnus Jaderberg, Chief Medical Officer at Targovax, held an introductory presentation on immuno-oncology at The Royal Academy of Engineers conference on cancer medicine in Stockholm 16 May 2016. The title of the conference was “Nya cancerläkemedel för individanpassad behandling” (New cancer medicines for individualized treatment). Directed at a general public audience, the various presentations take the viewer step by step in an easy to understand way through the currently ongoing revolution of cancer treatment, which is brought about by new, innovative immuno-oncology medicines.

    The video from the conference (in Swedish language only) is now available at: 
    iva.se/event/nya-cancerlakemedel-for-individanpassad-behandling

    Read more
  • Targovax ASA: Interim report first quarter 2016

    May 12, 2016

           

    Promising data for interim survival analysis of a first cohort of the ongoing open label, phase I/II of TG01/GM-CSF and gemcitabine in patients with resected pancreatic cancer
      Conducted an interim DTH immunological response of a second cohort of t (...) Read more
  • Targovax ASA: Registration of share capital increase following exercise of employee options

    May 9, 2016

    Reference is made to the notice of 14 April 2016 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee options. The share capital increase has today been registered in the Register of Business Enterprise (...)

    Read more
  • Targovax to present at BioEquity Europe and its first quarter 2016 results on May 11 - 12, 2016

    May 9, 2016

     BioEquity

    Targovax announces that Gunnar Gårdemyr, Chief Executive Officer, will hold a presentation at BioEquity Europe in Copenhagen, Denmark on Wednesday, May 11, 2016.

    The presentation will be available the same day at Targovax's website http://www.targovax.com/investors/presentations

    In (...)

    Read more
  • Exercise of employee share options in Targovax ASA

    April 29, 2016

    Reference is made to stock exchange notice of 14 April 2016 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options. As per 29 April 2016, 21,559 shares each with a par value of NOK 0.10 were subscribed by employees, including certain former e (...)

    Read more
  • Targovax ASA: Grant of restricted stock units to the Board of directors

    April 15, 2016

    Reference is made to the minutes from the ordinary general meeting in Targovax ASA (the company) regarding the remuneration to be paid to the board of directors and the implementation of a restricted stock unit (RSU) program for the board of directors.

    Under the RSU program, the board of directors  (...)

    Read more